DK0612321T3 - Pyridopyridazinon- og pyridazinthionforbindelser med PDE IV inhiberende aktivitet - Google Patents

Pyridopyridazinon- og pyridazinthionforbindelser med PDE IV inhiberende aktivitet

Info

Publication number: DK0612321T3
Authority: DK; Denmark
Prior art keywords: pyridazinethione; pyridopyridazinone; pde; compounds; inhibitory activity
Prior art date: 1991-10-09

Application number

DK92922090T

Other languages

English (en)

Inventor

Robert Stephen Wilhelm

Bradley Earl Loe

Bruce Henry Devens

Michael Grant Martin

Robert Alvarez

Original Assignee

Syntex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-09

Filing date

1992-10-08

Publication date

1999-12-13

1992-10-08 Application filed by Syntex Inc filed Critical Syntex Inc

1999-12-13 Application granted granted Critical

1999-12-13 Publication of DK0612321T3 publication Critical patent/DK0612321T3/da

Links

YQQSRZSUGBETRS-UHFFFAOYSA-N 1h-pyridazine-6-thione Chemical class SC1=CC=CN=N1 YQQSRZSUGBETRS-UHFFFAOYSA-N 0.000 title abstract 2
DYHGFTMEUMYPOC-UHFFFAOYSA-N 8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)pyrido[2,3-d]pyridazin-5-one Chemical compound [O-][N+](=O)C1=CC=CC(C=2C3=NC=CC=C3C(=O)N(CC=3C=CN=CC=3)N=2)=C1 DYHGFTMEUMYPOC-UHFFFAOYSA-N 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
229910052799 carbon Inorganic materials 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
150000002431 hydrogen Chemical class 0.000 abstract 2
KMUUDIJYIRNGRO-UHFFFAOYSA-N 2h-pyrido[3,2-c]pyridazin-3-one Chemical class N1=CC=CC2=NNC(=O)C=C21 KMUUDIJYIRNGRO-UHFFFAOYSA-N 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
150000001266 acyl halides Chemical class 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
239000000730 antalgic agent Substances 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
125000005605 benzo group Chemical group 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK92922090T 1991-10-09 1992-10-08 Pyridopyridazinon- og pyridazinthionforbindelser med PDE IV inhiberende aktivitet DK0612321T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US77567991A	1991-10-09	1991-10-09
PCT/US1992/008398 WO1993007146A1 (en)	1991-10-09	1992-10-08	Benzo and pyrido pyridazinone and pyridazinthione compounds with pde iv inhibiting activity

Publications (1)

Publication Number	Publication Date
DK0612321T3 true DK0612321T3 (da)	1999-12-13

Family

ID=25105161

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92922090T DK0612321T3 (da)	1991-10-09	1992-10-08	Pyridopyridazinon- og pyridazinthionforbindelser med PDE IV inhiberende aktivitet

Country Status (20)

Country	Link
EP (1)	EP0612321B1 (da)
JP (1)	JP3245165B2 (da)
KR (1)	KR100263494B1 (da)
AT (1)	ATE183745T1 (da)
AU (1)	AU670544B2 (da)
CA (1)	CA2117059C (da)
DE (1)	DE69229874T2 (da)
DK (1)	DK0612321T3 (da)
ES (2)	ES2135416T3 (da)
FI (1)	FI108229B (da)
GR (1)	GR3030969T3 (da)
HU (2)	HUT66969A (da)
IL (1)	IL103388A (da)
MX (1)	MX9205794A (da)
NO (1)	NO302888B1 (da)
NZ (1)	NZ244660A (da)
PT (1)	PT100938B (da)
TW (1)	TW365606B (da)
WO (1)	WO1993007146A1 (da)
ZA (1)	ZA927755B (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9200689D0 (en) *	1992-01-14	1992-03-11	Rhone Poulenc Agriculture	New compositions of matter
GB9314412D0 (en) *	1993-07-13	1993-08-25	Rhone Poulenc Agriculture	New compositions of matter
US5665754A (en) *	1993-09-20	1997-09-09	Glaxo Wellcome Inc.	Substituted pyrrolidines
US5466697A (en) *	1994-07-13	1995-11-14	Syntex (U.S.A.) Inc.	8-phenyl-1,6-naphthyridin-5-ones
KR970705562A (ko) *	1994-08-29	1997-10-09	오노다 마사요시	신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof)
US6069151A (en) *	1996-11-06	2000-05-30	Darwin Discovery, Ltd.	Quinolines and their therapeutic use
GB9712761D0 (en) *	1997-06-17	1997-08-20	Chiroscience Ltd	Quinolines and their therapeutic use
ES2137113B1 (es) *	1997-07-29	2000-09-16	Almirall Prodesfarma Sa	Nuevos derivados de triazolo-piridazinas heterociclicos.
ATE258930T1 (de) *	1997-12-15	2004-02-15	Altana Pharma Ag	Dihydrobenzifurane
EP0934933A1 (en) *	1998-02-06	1999-08-11	Byk Gulden Lomberg Chemische Fabrik GmbH	Phthalazinones
IT1303272B1 (it)	1998-10-29	2000-11-06	Zambon Spa	Derivati triciclici inibitori della fosfodiesterasi 4
UA71945C2 (en)	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja)	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
EP1212089B1 (en)	1999-08-21	2006-03-22	ALTANA Pharma AG	Synergistic combination of roflumilast and salmeterol
EE05386B1 (et) *	2001-02-15	2011-02-15	ALTANA�Pharma�AG	Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim
NZ529221A (en) *	2001-04-25	2005-04-29	Altana Pharma Ag	Phthalazinones with PDE-inhibiting properties for treatment of airway disorders and other inflammatory conditions
CZ20033205A3 (en)	2001-04-25	2004-03-17	Altana Pharma Ag	Piperazino-derivatives and their use as pde4 inhibitor
ES2195785B1 (es)	2002-05-16	2005-03-16	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
WO2004018450A1 (en) *	2002-08-10	2004-03-04	Altana Pharma Ag	Piperidine-n-oxide-derivatives
CA2494613C (en)	2002-08-10	2011-06-28	Altana Pharma Ag	Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
ES2211344B1 (es)	2002-12-26	2005-10-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
MXPA05010373A (es)	2003-04-01	2005-12-05	Applied Research Systems	Inhibidores de fosfodiesterasas en infertilidad.
EP1716133B1 (en)	2004-02-04	2008-03-26	Nycomed GmbH	2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
ES2251866B1 (es)	2004-06-18	2007-06-16	Laboratorios Almirall S.A.	Nuevos derivados de piridazin-3(2h)-ona.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en)	2007-06-04	2015-10-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PL383550A1 (pl) *	2007-10-15	2009-04-27	Uniwersytet Łódzki	Nowe pochodne benzeno- i pirydopirydazynonów
EP2810951B1 (en)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
ES2664873T3 (es)	2011-03-01	2018-04-23	Synergy Pharmaceuticals Inc.	Proceso de preparación de agonistas de guanilato ciclasa C
US20130116241A1 (en) *	2011-11-09	2013-05-09	Abbvie Inc.	Novel inhibitor compounds of phosphodiesterase type 10a
WO2013097052A1 (en)	2011-12-30	2013-07-04	Abbott Laboratories	Bromodomain inhibitors
US9545446B2 (en)	2013-02-25	2017-01-17	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
MX365950B (es)	2013-03-13	2019-06-19	Flatley Discovery Lab Llc	Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
CA2905435A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
SI3004138T1 (sl)	2013-06-05	2024-07-31	Bausch Health Ireland Limited	Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
KR102456567B1 (ko)	2013-08-09	2022-10-19	알데릭스, 인코포레이티드	인산염 수송을 억제하기 위한 화합물 및 방법
EP3265453B1 (en) *	2015-03-05	2022-06-29	Boehringer Ingelheim International GmbH	New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
JP6837052B2 (ja) *	2016-03-09	2021-03-03	日本曹達株式会社	ピリジン化合物およびその用途
CA3018802A1 (en)	2016-04-15	2017-10-19	Abbvie Inc.	Bromodomain inhibitors
WO2020237096A1 (en)	2019-05-21	2020-11-26	Ardelyx, Inc.	Combination for lowering serum phosphate in a patient
FR3105254B1 (fr)	2019-12-19	2022-08-12	Syctom Lagence Metropolitaine Des Dechets Menagers	Installation et procédé de gazéification hydrothermale de biomasse
TW202334140A (zh) *	2021-11-09	2023-09-01	美商維佳神經科學有限公司	作為骨髓細胞上表現之觸發受體２促效劑之雜環化合物及其使用方法
WO2025046523A1 (ko) *	2023-08-31	2025-03-06	삼진제약주식회사	신규한 피리도 피리다진온 유도체 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2805344B2 (ja) *	1989-07-11	1998-09-30	昭和電工株式会社	オレフィン重合触媒の製造方法およびオレフィンの重合方法
AU7238191A (en) *	1990-02-19	1991-09-03	Chugai Seiyaku Kabushiki Kaisha	Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom

1992
- 1992-10-08 HU HU9400949A patent/HUT66969A/hu unknown
- 1992-10-08 EP EP92922090A patent/EP0612321B1/en not_active Expired - Lifetime
- 1992-10-08 JP JP50707893A patent/JP3245165B2/ja not_active Expired - Fee Related
- 1992-10-08 PT PT100938A patent/PT100938B/pt not_active IP Right Cessation
- 1992-10-08 DK DK92922090T patent/DK0612321T3/da active
- 1992-10-08 KR KR1019940701129A patent/KR100263494B1/ko not_active Expired - Fee Related
- 1992-10-08 MX MX9205794A patent/MX9205794A/es not_active IP Right Cessation
- 1992-10-08 DE DE69229874T patent/DE69229874T2/de not_active Expired - Fee Related
- 1992-10-08 ES ES92922090T patent/ES2135416T3/es not_active Expired - Lifetime
- 1992-10-08 ES ES09201998A patent/ES2105920B1/es not_active Expired - Fee Related
- 1992-10-08 TW TW081108015A patent/TW365606B/zh active
- 1992-10-08 NZ NZ244660A patent/NZ244660A/en unknown
- 1992-10-08 IL IL103388A patent/IL103388A/xx not_active IP Right Cessation
- 1992-10-08 ZA ZA927755A patent/ZA927755B/xx unknown
- 1992-10-08 AU AU27815/92A patent/AU670544B2/en not_active Ceased
- 1992-10-08 CA CA002117059A patent/CA2117059C/en not_active Expired - Fee Related
- 1992-10-08 AT AT92922090T patent/ATE183745T1/de not_active IP Right Cessation
- 1992-10-08 WO PCT/US1992/008398 patent/WO1993007146A1/en not_active Ceased
1994
- 1994-04-05 NO NO941210A patent/NO302888B1/no not_active IP Right Cessation
- 1994-04-06 FI FI941567A patent/FI108229B/fi active
1995
- 1995-04-24 HU HU95P/P00113P patent/HU210814A9/hu unknown
1999
- 1999-08-26 GR GR990401632T patent/GR3030969T3/el unknown

Also Published As

Publication number	Publication date
FI941567A0 (fi)	1994-04-06
ES2135416T3 (es)	1999-11-01
EP0612321A1 (en)	1994-08-31
JP3245165B2 (ja)	2002-01-07
NO302888B1 (no)	1998-05-04
GR3030969T3 (en)	1999-11-30
DE69229874D1 (de)	1999-09-30
MX9205794A (es)	1993-04-01
HU9400949D0 (en)	1994-06-28
ES2105920A1 (es)	1997-10-16
JPH07500321A (ja)	1995-01-12
FI108229B (fi)	2001-12-14
KR100263494B1 (ko)	2000-08-01
PT100938A (pt)	1993-10-29
CA2117059A1 (en)	1993-04-15
DE69229874T2 (de)	1999-12-09
ZA927755B (en)	1994-04-08
IL103388A0 (en)	1993-03-15
WO1993007146A1 (en)	1993-04-15
AU670544B2 (en)	1996-07-25
NZ244660A (en)	1995-05-26
TW365606B (en)	1999-08-01
IL103388A (en)	1997-09-30
HUT66969A (en)	1995-01-30
NO941210L (no)	1994-04-05
ES2105920B1 (es)	1998-07-01
KR940702868A (ko)	1994-09-17
AU2781592A (en)	1993-05-03
FI941567L (fi)	1994-04-06
PT100938B (pt)	1999-10-29
HU210814A9 (en)	1995-08-28
ATE183745T1 (de)	1999-09-15
NO941210D0 (no)	1994-04-05
CA2117059C (en)	2003-05-20
EP0612321B1 (en)	1999-08-25

Publication	Publication Date	Title
DK0612321T3 (da)	1999-12-13	Pyridopyridazinon- og pyridazinthionforbindelser med PDE IV inhiberende aktivitet
CA2119572A1 (en)	1993-04-15	Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
FI953968A0 (fi)	1995-08-23	Antraniiliset happojohdannaiset
EP1035123A4 (en)	2001-12-12	NEW HETEROCYCLIC CONNECTIONS
MXPA05003193A (es)	2005-06-08	Compuesto de adenina novedoso y uso del mismo.
RU95112848A (ru)	1997-03-20	Гетеробициклические производные сульфонамида и сульфонового эфира, способы получения, антиопухолевое средство, фармакологическая композиция, способ лечения
IE822310L (en)	1983-03-24	Triazoloquinazolone derivatives
ES2113399T3 (es)	1998-05-01	Derivados de beta-oxo-beta-bencenopropano-tio-amida.
KR940701253A (ko)	1994-05-28	면역조절제 아자스피란
TW360655B (en)	1999-06-11	Heterocyclyl-ergoline derivatives
FI89594C (fi)	1993-10-25	Foerfarande foer framstaellning av farmakologiskt vaerdefull pyrrolidinfoerening
FI871253A0 (fi)	1987-03-20	1-/3-(2-dialkylaminoetoxi)-2 -tienyl/-3-fenyl-1-propanoner och deras syraadditionssalter, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska sammansaettningar.
DK0471856T3 (da)	1995-06-06	15-Deoxyprostaglandin-derivater
NO930844L (no)	1993-05-07	2-(2-substituerte pyrrolidinyltio)karbapenem-derivater
SE7713864L (sv)	1978-06-09	Nortropinkarbazatderivat och forfarande for framstellning av dem
DK0618917T3 (da)	1997-10-13	1Amino-2- (benzothiazolyl)methyl spiro isoquinolin-4(1h),3-pyrrolidin -1,2,3,5(2h)-tetroner og analoger deraf, der kan anvendes som aldosereduktaseinhibitorer.
KR970032864A (ko)	1997-07-22	골다공증 치료제